- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Activin ligand-trap biological therapy, Placebo, Normal Saline
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFPEF)
- Interventions
- Ferumoxytol infusion
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Obesity, Heart Failure
- Interventions
- NNC0487-0111, Placebo
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5,610 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 202
- States / cities
- Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 168 more
- Conditions
- Atrial Fibrillation, Diastolic Dysfunction, HFpEF - Heart Failure With Preserved Ejection Fraction
- Interventions
- As needed pharmacological rate control with beta-blocker (metoprolol tartrate, metoprolol succinate) or calcium channel blocker (diltiazem, verapamil)
- Drug
- Lead sponsor
- University of Vermont
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Burlington, Vermont
- Conditions
- HFpEF - Heart Failure With Preserved Ejection Fraction, Diabetic Cardiomyopathies
- Interventions
- Moderate-intensity continuous training (MCT), Resistance training, Weight loss
- Behavioral · Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Heart Failure With Preserved Ejection Fraction, Heart Failure With Mildly Reduced Ejection Fraction, Obesity
- Interventions
- Maridebart cafraglutide, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 5,056 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 106
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 94 more
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure With Normal Ejection Fraction
- Interventions
- Not listed
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 2
- States / cities
- Charleston, South Carolina
- Conditions
- Heart Failure With Preserved Ejection Fraction
- Interventions
- Cilostazol 100Mg Tab, Placebo
- Drug
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Heart Failure, Diastolic
- Interventions
- CoQ10, D-Ribose Oral Powder, Placebo pills, Placebo powder
- Drug · Other
- Lead sponsor
- University of Kansas Medical Center
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 216 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Kansas City, Kansas
- Conditions
- Heart Failure
- Interventions
- Paricalcitol
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Heart Failure, Obesity, Weight Loss, Heart Failure With Preserved Ejection Fraction
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Cardiovascular Diseases
- Interventions
- HBCR
- Other
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Heart Failure, Heart Failure, Systolic, Heart Failure, Diastolic, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV, Heart Failure，Congestive, Heart Failure With Reduced Ejection Fraction, Heart Failure With Normal Ejection Fraction, Heart Failure; With Decompensation
- Interventions
- CardioMEMS™ HF System
- Device
- Lead sponsor
- Abbott Medical Devices
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,358 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 125
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Fayetteville, Arkansas + 100 more
- Conditions
- Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
- Interventions
- TX000045- Dose A, TX000045- Dose B, Placebo
- Drug
- Lead sponsor
- Tectonic Therapeutic
- Industry
- Eligibility
- 18 Years to 83 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • San Francisco, California + 27 more
- Conditions
- Heart Failure With Preserved Ejection Fraction, Coronary Microvascular Dysfunction
- Interventions
- Cardiovascular Magnetic Resonance (CMR)
- Diagnostic Test
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Atrial Fibrillation (AF), Atrial Fibrillation (Paroxysmal), Persistent Atrial Fibrillation, Heart Failure With Preserved Ejection Fraction (HFPEF)
- Interventions
- progressive resistance training, combined aerobic + resistance training
- Behavioral
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 60 Years to 99 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Aging, Heart Failure With Preserved Ejection Fraction, Heart Failure With Reduced Ejection Fraction, Frailty, Physical Function, Quality of Life
- Interventions
- Inspiratory Muscle Training (IMT), Standard of Care
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 70 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Heart Failure With Normal Ejection Fraction
- Interventions
- Active lozenge, Placebo
- Dietary Supplement · Drug
- Lead sponsor
- MaineHealth
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Rockport, Maine
- Conditions
- Diastolic Heart Failure, Hypertensive Heart Disease
- Interventions
- DASH/sodium-restricted diet (DASH/SRD), Control Diet
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Heart Failure
- Interventions
- Placebo, Low Dose PF-07328948, Medium Dose PF-07328948, High Dose PF-07328948
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 620 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 28
- States / cities
- Beverly Hills, California • Lake Forest, California • Santa Maria, California + 17 more
- Conditions
- Transthyretin Amyloid Cardiomyopathy, Heart Failure With Preserved Ejection Fraction
- Interventions
- Scintigraphy
- Diagnostic Test
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 347 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 22
- States / cities
- Fairhope, Alabama • Huntsville, Alabama • Miami, Florida + 11 more
- Conditions
- Ischemic Heart Disease, Microvascular Coronary Artery Disease, Diastolic Dysfunction, Heart Failure With Preserved Ejection Fraction
- Interventions
- Echocardiography, Coronary flow reserve and index of microcirculatory dysfunction
- Diagnostic Test
- Lead sponsor
- Samsung Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2024
- U.S. locations
- 1
- States / cities
- Iowa City, Iowa
- Conditions
- HF - Heart Failure, Diabetes Mellitus
- Interventions
- Bumetanide 0.5 mg, dapaglifozin 5 mg, eplerenone 25 mg
- Drug
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- HFpEF - Heart Failure With Preserved Ejection Fraction, HFmrEF, ATTR-CM (Transthyretin Amyloid Cardiomyopathy), Left Ventricular Hypertrophy, Cardiac Amyloidosis
- Interventions
- Not listed
- Lead sponsor
- eMyosound SAS
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts